Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008–2017

Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008–2017

Objectives To detect the signals for drospirenone-containing oral contraceptives (DCOCs) and describe the reporting pattern of adverse events (AEs) caused by DCOCs compared with levonorgestrel/desogestrel/gestodene-containing (second/third generation) oral contraceptives.Design A descriptive analysi...

Detaylı Bibliyografya
Asıl Yazarlar:	Ha-Lim Jeon, Ju-Young Shin, Seung-Ah Choe, Yeri Lee, Ahhyung Choi, Yunha Noh
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2021-08-01
Seri Bilgileri:	BMJ Open
Online Erişim:	https://bmjopen.bmj.com/content/11/8/e045948.full

Benzer Materyaller

The benefits of estetrol addition to drospirenone for contraception
Yazar:: Jean Michel Foidart, PhD, MD, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

An insight into the use of estetrol-drospirenone as effective oral contraceptive
Yazar:: Himanshu Chaudhry, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Drospirenone-containing contraception: curative and preventive aspects of use
Yazar:: A V Ledina, ve diğerleri
Baskı/Yayın Bilgisi: (2015-02-01)

Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study.
Yazar:: Eun-Young Choi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Premenstrual syndrome: the effectiveness of treatment with a drospirenone-containing contraceptive
Yazar:: V. N. Prilepskaya, ve diğerleri
Baskı/Yayın Bilgisi: (2015-12-01)

Efficacy and safety of drospirenone-containing microdosage combined oral contraceptive use with starting contraception
Yazar:: A.R.Khachaturian, ve diğerleri
Baskı/Yayın Bilgisi: (2018-04-01)

First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea.
Yazar:: Yunha Noh, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

The estetrol-drospirenone-containing contraceptive as a drug of choice for patients with mastalgia
Yazar:: Mekan R. Orazov, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

CONTRACEPTION WITH DROSPIRENONE: EFFECT ON THE BODY WEIGHT AND SOME LIPID METABOLISM INDICATORS
Yazar:: A. A. Smetnik
Baskı/Yayın Bilgisi: (2016-12-01)

Effect of an estetrol/drospirenone contraceptive on sexual function in women of reproductive age
Yazar:: Mekan R. Orazov, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
Yazar:: Jerry KL Tan, ve diğerleri
Baskı/Yayın Bilgisi: (2009-11-01)

Benefits of using combined oral contraceptive with drospirenone in 24+4 overweight adolescents
Yazar:: I V Kuznetsova, ve diğerleri
Baskı/Yayın Bilgisi: (2014-02-01)

Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database
Yazar:: Chengcheng Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Simultaneous determination of ethinyl estradiol and drospirenone in oral contraceptive by high performance liquid chromatography
Yazar:: Viviane Benevenuti Silva, ve diğerleri
Baskı/Yayın Bilgisi: (2013-09-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
Yazar:: Chang-Zhu He, ve diğerleri
Baskı/Yayın Bilgisi: (2025-03-01)

Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
Yazar:: Jing Shi, ve diğerleri
Baskı/Yayın Bilgisi: (2025-03-01)

A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases
Yazar:: Shupeng Zou, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
Yazar:: Maria Antonietta Barbieri, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

Real-world treatment patterns for atopic dermatitis in South Korea
Yazar:: Ji Hyun Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Safety and evidence base of a combined oral contraceptive based on estherol and drospirenone: a brief summary
Yazar:: Mekan R. Orazov, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
Yazar:: Jirath Wichianpitaya, ve diğerleri
Baskı/Yayın Bilgisi: (2013-01-01)

Simultaneous total occlusion of two coronary arteries associated with use of drospirenone-ethinyl estradiol (oral contraceptive)
Yazar:: Hüsnü Atmaca, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
Yazar:: Shan Lin, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

The drospirenone only pill as a contraceptive option for breastfeeding women: First data on users’ acceptability and newborn development
Yazar:: Pedro Antonio Regidor, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Characteristics of uterine bleeding associated with an oral contraceptive containing drospirenone in combination with estetrol: A multicenter observational study
Yazar:: Irina V. Kuznetsova, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Modulatory Effects of Ethinyl Estradiol Plus Drospirenone Contraceptive Pill on Spontaneous and GnRH-Induced LH Secretion
Yazar:: Alessandro D. Genazzani, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Sexual health of women using combined oral contraceptive containing estetrol and drospirenone: A prospective observational study
Yazar:: Mekan R. Orazov, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Comparison of risks of thromboembolism of drospirenone-containing and nondrospirenone -containing combined oral contraceptive use: A meta-analysis
Yazar:: Wan-Lin Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database
Yazar:: Jie Li, ve diğerleri
Baskı/Yayın Bilgisi: (2025-03-01)

A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database
Yazar:: Shichao Cui, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Comparison of the lipophilicity parameters of drospirenone and lynestrenol
Yazar:: Agnieszka Kusztal, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Drospirenon v evolyutsiigormonal'noy kontratseptsii
Yazar:: Elena Anatol'evna Mezhevitinova, ve diğerleri
Baskı/Yayın Bilgisi: (2011-04-01)

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
Yazar:: Wenting Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Comparing the risk of deep vein thrombosis of two combined oral contraceptives: Norethindrone/ethinyl estradiol and drospirenone/ethinyl estradiol
Yazar:: Jennifer Stalas, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Ultrasound-Assisted Extraction, Followed by Gas Chromatography–Mass Spectrometry for the Simultaneous Quantification of Ethinyl Estradiol and Drospirenone in Contraceptive Formulations
Yazar:: Javier Peña, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Serious adverse events reported with benzimidazole derivatives: A disproportionality analysis from the World Health Organization's pharmacovigilance database.
Yazar:: Pamella Modingam, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
Yazar:: Hailong Li, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events
Yazar:: Yunha Noh, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Cardiovascular Adverse Events Associated with Prostate Cancer Treatment: A Disproportionality Analysis from the Food and Drug Administration Adverse Event Reporting System Database
Yazar:: Connor Frey
Baskı/Yayın Bilgisi: (2024-11-01)

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
Yazar:: Yongfu Song, ve diğerleri
Baskı/Yayın Bilgisi: (2025-03-01)